The Impact of FDA-Approved Novel Agents for Steroid-Refractory Chronic Graft vs. Host Disease on Treatment Patterns and Outcomes—A Single-Center Longitudinal Cohort Analysis.

Autor: Fridberg, Gil1,2 (AUTHOR) davidsha@tlvmc.gov.il, Amit, Odelia1,2 (AUTHOR) odeliaa@tlvmc.gov.il, Karni, Chen1 (AUTHOR) chenk@tlvmc.gov.il, Tshernichovsky, Dina1 (AUTHOR) dinat@tlvmc.gov.il, Shasha, David2,3 (AUTHOR) davidva@tlvmc.gov.il, Rouach, Vanessa2,4 (AUTHOR) amirbs@tlvmc.gov.il, Varssano, David2,5 (AUTHOR) ilango@tlvmc.gov.il, Bar-Shai, Amir2,6 (AUTHOR) giladwas@tlvmc.gov.il, Goldberg, Ilan2,7 (AUTHOR), Wasserman, Gilad2,8 (AUTHOR), Avivi, Irit1,2 (AUTHOR) iritavi@tlvmc.gov.il, Ram, Ron1,2 (AUTHOR) ronr@tlvmc.gov.il
Zdroj: Cancers. Oct2024, Vol. 16 Issue 20, p3521. 12p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje